Species differences in the formation of vabicaserin carbamoyl glucuronide

Drug Metabolism and Disposition

Volumn 38, Issue 4, 2010, Pages 581-590

  Tong, Zeen ^a   Chandrasekaran, Appavu ^a   DeMaio, William ^a   Jordan, Ronald ^a   Li, Hongshan ^a   Moore, Robin ^a   Poola, Nagaraju ^a   Burghart, Peter ^a   Hultin, Theresa ^a   Scatina, Joann ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBAMOYL GLUCURONIDE; DRUG METABOLITE; PLACEBO; UNCLASSIFIED DRUG; VABICASERIN;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG GLUCURONIDATION; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; LIVER MICROSOME; MALE; MONKEY; MOUSE; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RADIOACTIVITY; RANDOMIZED CONTROLLED TRIAL; RAT; SPECIES DIFFERENCE; STEADY STATE; URINARY EXCRETION;

ADULT; ANIMALS; AREA UNDER CURVE; AZEPINES; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOGS; DOUBLE-BLIND METHOD; FEMALE; GLUCURONIDES; HUMANS; MACACA FASCICULARIS; MALE; MICE; MICROSOMES, LIVER; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN AGONISTS; SPECIES SPECIFICITY; SPECTROPHOTOMETRY, ULTRAVIOLET;

ANIMALIA; CANIS FAMILIARIS; MUS; RATTUS;

EID: 77950288858     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028639     Document Type: Article

References (20)

1. Beconi MG, Mao A, Liu DQ, Kochansky C, Pereira T, Raab C, Pearson P, and Lee Chiu SH (2003) Metabolism and pharmacokinetics of a dipeptidyl peptidase IV inhibitor in rats, dogs, and monkeys with selective carbamoyl glucuronidation of the primary amine in dogs. Drug Metab Dispos 31:1269-1277.
2. Beconi MG, Reed JR, Teffera Y, Xia YQ, Kochansky CJ, Liu DQ, Xu S, Elmore CS, Ciccotto S, Hora DF, et al. (2007) Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs. Drug Metab Dispos 35:525-532.
3. Delbressine LP, Funke CW, van Tilborg M, and Kaspersen FM (1990) On the formation of carbamate glucuronides. Xenobiotica 20:133-134.
4. Dunlop J, Zhang J, Watts S, Ramamoorthy S, Harrison B, Barrett JE, Magolda R, Schecheter L, Pangalos MN, Stack G, et al. (2006) In vitro pharmacological profile of SCA-136, a novel 5-HT2C receptor selective agonist. 36th Annual Meeting for the Society of Neuroscience; 2006 Oct 14-18; Atlanta, GA. Society for Neuroscience, Washington, D.C.
5. Elvin AT, Keenaghan JB, Byrnes EW, Tenthorey PA, McMaster PD, Takman BH, Lalka D, Manion CV, Baer DT, Wolshin EM, et al. (1980) Tocainide conjugation in humans: novel biotransformation pathway for a primary amine. J Pharm Sci 69:47-49.
6. Fenselau C (1994) Acyl glucuronides as chemically reactive intermediates, in Conjugation-Deconjugation Reactions in Drug Metabolism and Toxicity (Kauffman FC ed) pp 367-389, Springer-Verlag, Berlin-Heidelberg.
7. Gipple KJ, Chan KT, Elvin AT, Lalka D, and Axelson JE (1982) Species differences in the urinary excretion of the novel primary amine conjugate: tocainide carbamoyl-O-β-D-glucuronide. J Pharm Sci 71:1011-1014.
8. Greenaway W and Whatley F (1987) Formation of N-carboxy compounds during trimethyl-silanization of amino acids in the presence of carbon dioxide. J Chromatogr 409:383-389.
9. Mako B, Poola NR, Posener JA, and Paul J (2008) Safety, tolerability, and pharmacokinetics of multiple ascending oral doses of vabicaserin, a serotonin 2C agonist in subjects with schizophrenia and schizoaffective disorder. Clin Pharm Ther 83 (Suppl 1):S21.
10. Marquis KL, Dunlop J, Ramamoorthy S, Beyer CE, Lin Q, Brennan J, Piesla MJ, Ashby CRJ, Harrison B, Magolda R, et al. (2006) SCA-136: a novel 5-HT2C receptor agonist possessing atypical antipsychotic-like effects in preclinical models. 36th Annual Meeting for the Society of Neuroscience; 2006 Oct 14-18; Atlanta, GA. Society for Neuroscience, Washington, D.C.
11. Morrow JS, Keim P, and Gurd FR (1974) CO2 adducts of certain amino acids, peptides, and sperm whale myoglobin studied by carbon 13 and proton nuclear magnetic resonance. J Biol Chem 249:7484-7494.
12. Posener JA, Mako B, Abell M, Raje S, Plotka A, Fruncillo R, and Paul J (2007) Safety, pharmacokinetics (PK) and pharmacodynamics (PD) of ascending single oral doses of SCA-136 in healthy subjects. Clin Pharm Ther 81 (Suppl 1):S64-S65.
13. Ramji JV, Keogh JP, Blake TJ, Broom C, Chenery RJ, Citerone DR, Lewis VA, Taylor AC, and Yeulet SE (1999) Disposition of ropinirole in animals and man. Xenobiotica 29:311-325.
14. Schaefer WH (2006) Reaction of primary and secondary amines to form carbamic acid glucuronides. Curr Drug Metab 7:873-881.
15. Senda C, Toda S, Tateishi M, Kobayashi K, Igarashi T, and Chiba K (2003) Mexiletine carbonyloxy beta-D-glucuronide: a novel metabolite in human urine. Xenobiotica 33:871-884.
16. A receptor partial agonist in Sprague-Dawley rats and cynomolgus monkeys: identification of two unique N-carbamoyl metabolites. Drug Metab Dispos 33:1688-1699.
17. 2 nicotinic acetylcholine receptor partial agonist in Sprague-Dawley rats and the dispositional characterization of its N-carbamoyl glucuronide metabolite. Drug Metab Dispos 37:1480-1489.
18. Spahn-Langguth H and Benet LZ (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism? Drug Metab Rev 24:5-47.
19. Tremaine LM, Stroh JG, and Ronfeld RA (1989) Characterization of a carbamic acid ester glucuronide of the secondary amine sertraline. Drug Metab Dispos 17:58-63.
20. Wacker DA and Miller KJ (2008) Agonists of the serotonin 5-HT2C receptor: preclinical and clinical progression in multiple diseases. Curr Opin Drug Discov Devel 11:438-445.